Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

NCT01712425 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

BIOLOGICAL: 0-24 week prime/boost regimen
BIOLOGICAL: 0-8 week prime/boost regimen

Sponsor

IrsiCaixa

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]